MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-26-2026
22nd Century Group Operating Cycle 2011-2026 | XXII
Annual Operating Cycle 22nd Century Group
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 169 | 107 | 127 | 83.7 | 104 | 55.9 | 44.3 | 55.6 | 90.3 | 90 | 111 | 1.54 K | 1.11 K | 7.4 K | 600 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 7.4 K | 44.3 | 779 |
Quarterly Operating Cycle 22nd Century Group
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 171 | 168 | 118 | - | 106 | 89.6 | 102 | - | 441 | 343 | 274 | - | 76.8 | 64.8 | 43.8 | - | 49.8 | 48.3 | 58.9 | 27 | 53.7 | 60.4 | 48.5 | 10.9 | 44.1 | 48.6 | 50.5 | 11.1 | 58.2 | 52.6 | 61.4 | 14.7 | 80.8 | 96.2 | 20.4 | 1.12 | 1.21 | 1.32 | 1.39 | 1.59 | 85.5 | 2.03 | 3.79 | - | 616 | - | - | - | 6.24 K | - | - | - | - | - | - | - | 20.4 | 44.2 | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 6.24 K | 1.12 | 231 |
Operating Cycle of other stocks in the Biotechnology industry
| Issuer | Operating Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
3.11 K | - | 5743.5 % | $ 69.7 M |  Canada |
 |
MannKind Corporation
MNKD
|
457 | $ 3.56 | 24.48 % | $ 1.09 B |  USA |
 |
AgeX Therapeutics
AGE
|
186 | - | -10.17 % | $ 12.2 K | USA |
 |
I-Mab
IMAB
|
271 | - | - | $ 866 M |  China |
 |
Bio-Techne Corporation
TECH
|
224 | $ 47.41 | -16.36 % | $ 7.47 B | USA |
 |
United Therapeutics Corporation
UTHR
|
198 | $ 596.76 | 4.29 % | $ 26.4 B | USA |
 |
Midatech Pharma plc
MTP
|
245 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
12.8 | - | - | $ 40.3 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
32 | - | -1.52 % | $ 24.7 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
104 | - | - | - |  Russia |
 |
INmune Bio
INMB
|
19.9 K | $ 1.52 | -1.3 % | $ 37.6 M | USA |
 |
Exelixis
EXEL
|
140 | $ 48.7 | 9.64 % | $ 13.2 B | USA |
 |
ACADIA Pharmaceuticals
ACAD
|
332 | $ 21.48 | -3.89 % | $ 3.56 B | USA |
 |
Fortress Biotech
FBIO
|
325 | - | - | $ 71.1 M | USA |
 |
Advaxis
ADXS
|
88.1 | - | -9.65 % | $ 45.9 M | USA |
 |
Esperion Therapeutics
ESPR
|
99.7 | $ 3.15 | 1.19 % | $ 655 M | USA |
 |
Aeterna Zentaris
AEZS
|
115 | - | 5.93 % | $ 314 M | Canada |
 |
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | USA |
 |
Aptinyx
APTX
|
46.9 | - | -39.0 % | $ 4.57 M | USA |
 |
Albireo Pharma
ALBO
|
40.8 | - | -0.23 % | $ 916 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
291 | $ 24.17 | 3.2 % | $ 3.08 B | USA |
 |
Alpine Immune Sciences
ALPN
|
154 | - | - | $ 2.17 B | USA |
 |
Aridis Pharmaceuticals
ARDS
|
59 | - | 17.91 % | $ 11.1 M | USA |
 |
CRISPR Therapeutics AG
CRSP
|
1.1 K | $ 55.08 | 5.15 % | $ 4.95 B |  Schweiz |
 |
Autolus Therapeutics plc
AUTL
|
129 | $ 1.7 | 3.66 % | $ 452 M | Britain |
 |
Ayala Pharmaceuticals
AYLA
|
61.7 | - | - | $ 7.46 M |  Israel |
 |
Завод ДИОД
DIOD
|
64.6 | - | - | - | Russia |